Investor Relations


We intend to continue our business development effort by adding other proven domestic and international biotechnology partners to monetize the China health care market

  • Dec 5, 2020
    ASH 2020, United States

    An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

  • Aug 30, 2020
    Rockville, MD

    25th Annual Conference of the Chinese Biopharmaceutical Association-USA (CBA)

  • Jul 13, 2020
    Gaithersburg, MD

    CBMG R&D Showcase and Updates to Clinical Programs

  • Dec 7, 2019
    Annual Meeting of the American Society of Hematology (ASH), Orlando, Florida

    Developing a Novel Anti-BCMA CAR-T for Relapsed or Refractory Multiple Myeloma

  • Sep 11, 2019
    Boston, MA

    CAR-TCR Summit

  • Mar 1, 2019
    New York

    Leerink Partners 8th Annual Global Healthcare Conference

  • Feb 11, 2019
    New York

    CBMG Fact Sheet

  • Oct 29, 2018
    Shanghai, China

    CBMG Immuno-Oncology Updates

  • Oct 2, 2018
    Cantor Fitzgerald 2018 Global Healthcare Conference, NY

    Innovating Cancer and Degenerative Disease Treatment In China

  • Mar 16, 2018
    Hangzhou, China

    China Healthcare Investing & Partnering Symposium (CHIPS) AlloJoin KOA data